UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report

Cancer Immunology, Immunotherapy, 2017-01, Vol.66 (1), p.45-50

2017

Volltextzugriff (PDF)

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

Translational lung cancer research, 2018-09, Vol.7 (S3), p.S208-S210

2018

Volltextzugriff (PDF)

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

Cancers, 2022-10, Vol.14 (21), p.5225

2022

Volltextzugriff (PDF)

Malignant mesothelioma clinical trial combines immunotherapy drugs

Immunotherapy, 2018-04, Vol.10 (5), p.341-344

2018

Volltextzugriff (PDF)

Ethics of Patient-Clinician Boundaries in Oncology: Communication Strategies for Promoting Clinician Well-Being and Quality Patient Care

JCO oncology practice, 2024-08, Vol.20 (8), p.1016-1020

2024

Volltextzugriff (PDF)

Pathology of Seminoma Coinciding With Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

Curēus (Palo Alto, CA), 2021-07

2021

Volltextzugriff (PDF)

662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A754-A754

2023

Volltextzugriff (PDF)

Colonic Adenocarcinoma with Plasmacytoid Feature: Histopathology and Molecular Characteristics of a Rare Neoplasm with an Unusual Presentation

Case reports in pathology, 2022-02, Vol.2022, p.2640456-5

2022

Volltextzugriff (PDF)

Artist's statement: Empathirises

Academic medicine, 2013-03, Vol.88 (3), p.321-321

Chatwal, Monica

2013

Volltextzugriff (PDF)

A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.5075-5075

2022

Volltextzugriff (PDF)

Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.140-140

2023

Volltextzugriff (PDF)

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS245-TPS245

2024

Volltextzugriff (PDF)

Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.TPS713-TPS713

2024

Volltextzugriff (PDF)

Fear of Saying No (FOSNO): Setting Boundaries With Our Patients and Ourselves

American Society of Clinical Oncology educational book, 2023-05, Vol.43, p.e390598-e390598

2023

Volltextzugriff (PDF)

Mindful fellows: Study results from a pilot wellness curriculum in hematology oncology

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.10508-10508

2019

Volltextzugriff (PDF)

Building resilient oncologists: A feasibility study of a resiliency curriculum for hematology oncology fellows

Journal of clinical oncology, 2020-05, Vol.38 (15_suppl), p.TPS11043-TPS11043

2020

Volltextzugriff (PDF)

Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.521-521

2023

Volltextzugriff (PDF)

Initial tumor flare or mixed tumor response following single PD-1 vs. dual PD-1/CTLA-4 blockade in non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21037-e21037

2018

Volltextzugriff (PDF)

A feasibility study to examine the role of a mindfulness-based wellness curriculum for early clinical trainees

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS11020-TPS11020

2018

Volltextzugriff (PDF)

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Cancer drug resistance, 2023-01, Vol.6 (2), p.314-326

2023

Volltextzugriff (PDF)

Outcomes and Evolving Treatment Paradigms for Small Cell Carcinoma of the Bladder

International journal of radiation oncology, biology, physics, 2020-10, Vol.108 (2), p.E35-E35

2020

Volltextzugriff (PDF)

Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents

Expert review of respiratory medicine, 2017-10, Vol.11 (10), p.791-805

2017

Volltextzugriff (PDF)

Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.TPS9112-TPS9112

2018

Volltextzugriff (PDF)

A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology

JCO oncology practice, 2020-04, Vol.16 (4), p.191-199

2020

Volltextzugriff (PDF)

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Blood, 2014-12, Vol.124 (21), p.2525-2525

2014

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(26)
Mit Volltextzugriff
(22)

Publikationsform

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(11)
Science & Technology
(11)
Oncology
(8)
Humans
(6)
Immunotherapy
(5)
Cancer Therapies
(3)
Chemotherapy
(3)
Metastasis
(3)
Antineoplastic Agents, Immunological - Therapeutic Use
(2)
Clinical Trials As Topic
(2)
Immunology
(2)
Immunotherapy - Methods
(2)
Pathology
(2)
Patients
(2)
Respiratory System
(2)
Abiraterone
(1)
Adaptive Therapy
(1)
Adjuvant
(1)
Allografts
(1)
Allotransplant
(1)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report

Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?

A Phase 1b Adaptive Androgen Deprivation Therapy Trial in Metastatic Castration Sensitive Prostate Cancer

Malignant mesothelioma clinical trial combines immunotherapy drugs

Ethics of Patient-Clinician Boundaries in Oncology: Communication Strategies for Promoting Clinician Well-Being and Quality Patient Care

Pathology of Seminoma Coinciding With Small Lymphocytic Lymphoma/Chronic Lymphocytic Leukemia

662 Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Colonic Adenocarcinoma with Plasmacytoid Feature: Histopathology and Molecular Characteristics of a Rare Neoplasm with an Unusual Presentation

Artist's statement: Empathirises

A phase 1b adaptive androgen deprivation therapy trial in metastatic castration sensitive prostate cancer

Early results from a phase 1, multicenter trial of PSCA-specific GoCAR T cells (BPX-601) in patients with metastatic castration-resistant prostate cancer (mCRPC)

A phase IIa study of sequential ("first strike, second strike") therapies, modeled on evolutionary dynamics of anthropocene extinctions, for high-risk metastatic castration-sensitive prostate cancer

Phase I/II study of ipilimumab plus nivolumab (IPI-NIVO) combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Fear of Saying No (FOSNO): Setting Boundaries With Our Patients and Ourselves

Mindful fellows: Study results from a pilot wellness curriculum in hematology oncology

Building resilient oncologists: A feasibility study of a resiliency curriculum for hematology oncology fellows

Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma

Initial tumor flare or mixed tumor response following single PD-1 vs. dual PD-1/CTLA-4 blockade in non-small cell lung cancer (NSCLC)

A feasibility study to examine the role of a mindfulness-based wellness curriculum for early clinical trainees

Revisiting mechanisms of resistance to immunotherapies in metastatic clear-cell renal-cell carcinoma

Outcomes and Evolving Treatment Paradigms for Small Cell Carcinoma of the Bladder

Anti PD-L1 combined with other agents in non-small cell lung cancer: combinations with non-immuno-oncology agents

Phase I/II study of nivolumab and ipilimumab combined with nintedanib in advanced NSCLC

A Call to Action: Ethics Committee Roundtable Recommendations for Addressing Burnout and Moral Distress in Oncology

Racial Disparity in Patients with Multiple Myeloma Are Blunted in the Era Novel Therapies

Suchergebnisse filtern